U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula CH5N3.ClH
Molecular Weight 95.531
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Guanidine Hydrochloride

SMILES

Cl.NC(N)=N

InChI

InChIKey=PJJJBBJSCAKJQF-UHFFFAOYSA-N
InChI=1S/CH5N3.ClH/c2-1(3)4;/h(H5,2,3,4);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH5N3
Molecular Weight 59.0705
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Curator's Comment: The study was performed on rats.

Originator

Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
GUANIDINE HYDROCHLORIDE

Approved Use

Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis.

Launch Date

1939
PubMed

PubMed

TitleDatePubMed
Presynaptic imidazoline receptors. New developments in characterization and classification.
1999 Jun 21
[The study of the Ca2+ role in cytotoxic response of human cells in culture to the action of xenobiotics].
2000
The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: the significance of viral protein 2C.
2000 Apr
Dihydrofolate reductase from Thermotoga maritima.
2001
Expression and refolding of full-length human TIMP-1.
2001
Evolution and physiological roles of phosphagen systems.
2001
Demineralized bone matrix as a biological scaffold for bone repair.
2001 Apr
Kinetics of unfolding and folding from amide hydrogen exchange in native ubiquitin.
2001 Apr
Strain-specified relative conformational stability of the scrapie prion protein.
2001 Apr
The structure of human mitochondrial branched-chain aminotransferase.
2001 Apr
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.
2001 Apr
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
2001 Apr 12
Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site.
2001 Apr 24
Equilibrium unfolding of dimeric desulfoferrodoxin involves a monomeric intermediate: iron cofactors dissociate after polypeptide unfolding.
2001 Apr 24
Intensely positively charged perineuronal nets in the adult rat brain as detected by staining with anionic iron colloid.
2001 Feb
Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes.
2001 Feb
Stabilization of hen egg white lysozyme by a cavity-filling mutation.
2001 Feb
Metric engineering of soft molecular host frameworks.
2001 Feb
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions].
2001 Feb
Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients.
2001 Feb
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.
2001 Feb
Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production.
2001 Feb
Endogenous guanidino compounds as uremic neurotoxins.
2001 Feb
Human abdominal aortic aneurysm is characterized by decreased versican concentration and specific downregulation of versican isoform V(0).
2001 Feb 1
Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells.
2001 Feb 16
Molecular specificities of antibodies against ovine and murine recombinant prion proteins.
2001 Feb 16
Solid-phase guanidinylation as a diversification strategy of poly-L-proline type II peptide mimic scaffolds.
2001 Feb 22
Equilibrium unfolding of Bombyx mori glycyl-tRNA synthetase.
2001 Feb 9
Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry.
2001 Jan
Phaeochromocytoma: an unusual cause of hypertension in pregnancy.
2001 Jan
Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates.
2001 Jan 1
Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations.
2001 Jan 1
Limited tryptic hydrolysis of pea legumin: molecular mass and conformational stability of legumin-T.
2001 Jan 10
Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.
2001 Jan 12
Surprisingly high stability of barley lipid transfer protein, LTP1, towards denaturant, heat and proteases.
2001 Jan 19
A kinetic folding intermediate probed by native state hydrogen exchange.
2001 Jan 19
[Antibody avidity: use for the diagnosis of HIV early infection].
2001 Jan-Feb
Structural basis of the Na+/H+ exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator.
2001 Jun 8
Proteoglycans and hyaluronan in human fetal membranes.
2001 Mar
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release.
2001 Mar
Major differences in stability and dimerization properties of two chimeric mutants of human stefins.
2001 Mar 1
The synthesis of beta-peptides containing guanidino groups.
2001 Mar 12
Matrix proteins from insect pliable cuticles: are they flexible and easily deformed?
2001 Mar 15
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride.
2001 Mar 20
Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants.
2001 Mar 23
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.
2001 Mar 30
The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling: fractionation of conformational isomers of alpha-lactalbumin.
2001 Mar 30
The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase.
2001 Mar 9
Proton and metal ion-dependent assembly of a model diiron protein.
2001 May
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
2001 May 15
Patents

Sample Use Guides

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration: Oral
In Vitro Use Guide
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:49:51 GMT 2025
Edited
by admin
on Mon Mar 31 17:49:51 GMT 2025
Record UNII
3YQC9ZY4YB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Guanidine Hydrochloride
II   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
Systematic Name English
GUANIDINE HCL
INCI  
INCI  
Preferred Name English
GUANIDINE HYDROCHLORIDE [II]
Common Name English
Guanidine hydrochloride [WHO-DD]
Common Name English
NSC-755884
Code English
GUANIDINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
GUANIDINE HYDROCHLORIDE [MART.]
Common Name English
GUANIDINE HYDROCHLORIDE [VANDF]
Common Name English
GUANIDINE HYDROCHLORIDE [MI]
Common Name English
GUANIDINE HYDROCHLORIDE [USP-RS]
Common Name English
GUANIDINIUM CHLORIDE
Common Name English
Code System Code Type Description
NCI_THESAURUS
C45678
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
CONCEPT Industrial Aid
NCI_THESAURUS
C47551
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
NSC
755884
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
RXCUI
50676
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY RxNorm
CAS
50-01-1
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
PUBCHEM
5742
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
EVMPD
SUB14035MIG
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
RS_ITEM_NUM
1302134
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
DRUG BANK
DBSALT000737
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID7058757
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL821
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
MERCK INDEX
m5867
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
Guanidinium chloride
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
FDA UNII
3YQC9ZY4YB
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
CHEBI
32735
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
SMS_ID
100000077897
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-002-3
Created by admin on Mon Mar 31 17:49:51 GMT 2025 , Edited by admin on Mon Mar 31 17:49:51 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY